Osteoprotegerin increases parallel to insulin resistance in obese adolescents. (3rd April 2019)
- Record Type:
- Journal Article
- Title:
- Osteoprotegerin increases parallel to insulin resistance in obese adolescents. (3rd April 2019)
- Main Title:
- Osteoprotegerin increases parallel to insulin resistance in obese adolescents
- Authors:
- Kotanidou, Eleni P.
Kotanidis, Christos P.
Giza, Styliani
Serbis, Anastasios
Tsinopoulou, Vasiliki-Regina
Karalazou, Paraskevi
Tzimagiorgis, Georgios
Galli-Tsinopoulou, Assimina - Abstract:
- ABSTRACT: Purpose/Aim of the Study : Osteoprotegerin (OPG) is an α tumor necrosis factor receptor superfamily glucoprotein that acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL), exerting an antiresoptive bone effect. It was recently shown that OPG/RANKL axis is activated during vascular calcification, contributing to atherosclerotic lesions formation. Additionally, OPG levels are charachterized as an independent risk factor for overall vascular mortality in obese adults. We aimed to investigate OPG levels in children/adolescents with obesity and explore possible relations with obesity-related insulin resistance (IR).Material and Methods : A total of 160 participants (85 obese) were enrolled. Participants with obesity underwent an oral glucose tolerance test. IR was evaluated according to the homeostasis model assessment-insulin resistance index. Serum OPG levels were determined.Results : OPG levels did not differ significantly between obese subjects and controls in the total sample ( p = 0.133). However, in the adolescents' subgroup, serum OPG levels were significantly increased in obesity ( p = 0.019). After stratifying participants according to their IR status, only subjects with both obesity and IR exhibited increased OPG levels compared to controls ( p < 0.001). Factor analysis further associated OPG levels variation to insulin levels variation and to IR.Conclusions : Obese individuals demonstrate increased serum OPG levelsABSTRACT: Purpose/Aim of the Study : Osteoprotegerin (OPG) is an α tumor necrosis factor receptor superfamily glucoprotein that acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL), exerting an antiresoptive bone effect. It was recently shown that OPG/RANKL axis is activated during vascular calcification, contributing to atherosclerotic lesions formation. Additionally, OPG levels are charachterized as an independent risk factor for overall vascular mortality in obese adults. We aimed to investigate OPG levels in children/adolescents with obesity and explore possible relations with obesity-related insulin resistance (IR).Material and Methods : A total of 160 participants (85 obese) were enrolled. Participants with obesity underwent an oral glucose tolerance test. IR was evaluated according to the homeostasis model assessment-insulin resistance index. Serum OPG levels were determined.Results : OPG levels did not differ significantly between obese subjects and controls in the total sample ( p = 0.133). However, in the adolescents' subgroup, serum OPG levels were significantly increased in obesity ( p = 0.019). After stratifying participants according to their IR status, only subjects with both obesity and IR exhibited increased OPG levels compared to controls ( p < 0.001). Factor analysis further associated OPG levels variation to insulin levels variation and to IR.Conclusions : Obese individuals demonstrate increased serum OPG levels during puberty. Obesity per se is not the potent factor for this increase; indeed, IR accompanying obesity seems to exert a fundamental role in OPG upregulation. … (more)
- Is Part Of:
- Endocrine research. Volume 44:Number 1/2(2019)
- Journal:
- Endocrine research
- Issue:
- Volume 44:Number 1/2(2019)
- Issue Display:
- Volume 44, Issue 1/2 (2019)
- Year:
- 2019
- Volume:
- 44
- Issue:
- 1/2
- Issue Sort Value:
- 2019-0044-NaN-0000
- Page Start:
- 9
- Page End:
- 15
- Publication Date:
- 2019-04-03
- Subjects:
- Adolescents -- children -- insulin resistance -- obesity -- οsteoprotegerin
Endocrinology, Experimental -- Periodicals
Endocrinology -- Periodicals
Endocrinology -- Periodicals
Research -- Periodicals
616.4 - Journal URLs:
- http://informahealthcare.com/loi/erc ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/07435800.2018.1480630 ↗
- Languages:
- English
- ISSNs:
- 0743-5800
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3740.469000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9960.xml